Loading company…
Sparrow Pharmaceuticals develops treatments for hypercortisolism and inflammatory disorders.
Founded in 2013 and based in Oregon, US, Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company developing treatments for hypercortisolism, autoimmune and inflammatory conditions. Its drug candidates include SPI-62 and SPI-62 plus prednisolone. In June 2025, it raised USD 61.84 million in Series B funding co-led by Forbion and RA Capital Management.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in